 No, we're not doomed because placebo-controlled trials will be very difficult in this area. There's two ways this is commonly tackled in other literatures in medicine and psychiatry. The first is if MAPS were to carry out a study and say they combine MDMA and psychotherapy in one arm as they did, and in the other arm, they do the best available treatment for MDMA.